References
- Wolk A. Diet, lifestyle and risk of prostate cancer. Acta Oncol 2005; 44: 277–81
- Albertsen PC. Is screening for prostate cancer with prostate specific antigen an appropriate public health measure?. Acta Oncol 2005; 44: 255–64
- Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347(11)781–9
- Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352(19)1977–84
- Glimelius B, Steineck G. Low evidence of radiation therapy in prostate cancer–a plea for intensified scientific activity. Acta Oncol 2004; 43(4)311–5
- Malmström PU. The role of lymph node staging in prostatic carcinoma. Acta Oncol 2005;44: 593–98.
- Nilsson S, Norlen BJ, Widmark A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol 2004; 43(4)316–81
- Wahlgren T, Nilsson S, Ryberg M, Lennernäs B, Brandberg Y. Combined curative radiotherapy including HDR brachytherapy and androgen depreviation in localized prostate cancer–A prospective assessment of acute and late treatment toxicity. Acta Oncol 2005;44: 633–43.
- Hoeller U, Tribius S, Kuhlmey A, Grader K, Fehlauer F, Alberti W. Increasing the rate of late toxicity by changing the score? A comparison of RTOG/EORTC and LENT/SOMA scores. Int J Radiat Oncol Biol Phys 2003; 55(4)1013–8
- Fowler J F. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 2005; 44: 265–76
- Damber J.-E Endocrine therapy for prostate cancer. Acta Oncol 2005;44: 605–609.
- Ullén A, Lennartsson L, Harmenberg U, Hjelm-Eriksson M, Kälkner KM, Lennernäs B, et al Additative/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol 2005;44: 644–50.
- Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351(15)1502–12
- Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351(15)1513–20
- Vallbo C, Damber J.-E. Thrombospondins, metallo-proteases and thrombospondin receptors messenger RNA and protein expression in different tumour sublines of the Dunning prostate cancer model. Acta Oncol 2005; 44: 293–8
- Essand M Gene therapy and immunotherapy of prostate cancer–Adenoviral-based strategies. Acta Oncol 2005;44: 610–27.